DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Dendritic Cell Activating Scaffold in Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: WDVAX

First Posted Date: 2012-12-20

Last Posted Date: 2025-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01753089

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Ziv-aflibercept

First Posted Date: 2012-12-11

Last Posted Date: 2020-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT01747551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2

Terminated

Conditions: T-cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone
Drug: Filgrastim
Drug: Plerixafor
Procedure: Stem Cell Collection
Drug: Palifermin
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2012-12-10

Last Posted Date: 2023-01-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01746173

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: BKM120
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2012-12-05

Last Posted Date: 2019-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01741753

Locations: 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Standard Dissemination
Behavioral: Capacity Enhancement

First Posted Date: 2012-12-04

Last Posted Date: 2019-06-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 348

Registration Number: NCT01740219

Locations: 🇺🇸
University of Massachusetts Boston, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Tufts University, Medford, Massachusetts, United States

Cabozantinib for Metastatic Triple Negative BrCa

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2012-11-30

Last Posted Date: 2016-12-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01738438

Locations: 🇺🇸
Dana-Farber Cancer Institute at Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cisplatin + RT for Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2012-08-29

Last Posted Date: 2021-08-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT01674842

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber at Milford, Milford, Massachusetts, United States
🇺🇸
Dana Farber at South Shore Hospital, Weymouth, Massachusetts, United States

and more 2 locations

Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Radiation: post-mastectomy radiation therapy (PMRT)
Device: tissue expander (TE)
Device: acellular dermal matrix (ADM)

First Posted Date: 2012-08-14

Last Posted Date: 2019-08-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01664091

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Not Applicable

Withdrawn

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ferumoxytol

First Posted Date: 2012-08-13

Last Posted Date: 2020-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01663090

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

and more 1 locations

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Bendamustine
Drug: Cytarabine

First Posted Date: 2012-08-10

Last Posted Date: 2025-04-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01661881

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy